The Effectiveness of Acceptance and Commitment Therapy and Compassion-Focused Therapy on Death Anxiety and Fear of Falling in Patients with Multiple Sclerosis: A Quasi-Experimental Study

Journal of Rafsanjan University of Medical Sciences, Год журнала: 2025, Номер 23(8), С. 677 - 690

Опубликована: Янв. 1, 2025

The Effectiveness of Acceptance and Commitment Therapy Compassion-Focused on Death Anxiety Fear Falling in Patients with Multiple Sclerosis: A Quasi-Experimental Study

Язык: Английский

---

Clinical and radiological activity after extended interval and standard interval dosing of ocrelizumab in multiple sclerosis: A systematic review and meta-analysis

Neurological Sciences, Год журнала: 2025, Номер unknown

Опубликована: Апрель 4, 2025

Язык: Английский

---

The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis

Multiple Sclerosis Journal - Experimental Translational and Clinical, Год журнала: 2024, Номер 10(2)

Опубликована: Апрель 1, 2024

Background Many patients report a wearing-off phenomenon with monoclonal antibody treatment for multiple sclerosis in which perceived benefits wear off before the next dose is due. Objectives To determine prevalence of effect, symptoms experienced, impact on satisfaction, and associated patient characteristics. Methods Patients receiving natalizumab, ocrelizumab, ofatumumab, or rituximab at tertiary center were invited to take an online survey interrogating their experience. Additional history characteristic data collected. Logistic regression was used if characteristics predicted effect linear evaluate satisfaction. The models adjusted age, disease duration, race, sex, body mass index, education, depression as measured by Patient Health Questionnaire-9. Results We received 258 qualifying responses 141 (54.7%) reported phenomenon. most common symptom fatigue (47.7%). Higher Questionnaire-9 scores significantly (OR = 1.02, p 0.005). (β −0.52, 0.04) higher −0.09, < 0.01) reduced Conclusion common, depression, reduces Research addressing mitigation strategies needed.

Язык: Английский

---

Kynurenines and Inflammation: A Remarkable Axis for Multiple Sclerosis Treatment

Pharmaceuticals, Год журнала: 2024, Номер 17(8), С. 983 - 983

Опубликована: Июль 25, 2024

Multiple sclerosis (MS) is a chronic inflammatory autoimmune neurological disease characterized by the recurrent appearance of demyelinating lesions and progressive disability. Currently, there are multiple disease-modifying treatments, however, significant need to develop new therapeutic targets, especially for forms disease. This review article provides an overview most recent studies aimed at understanding processes that activated in response accumulation kynurenine pathway (KP) metabolites, which exacerbate imbalance between immune system cells (e.g., Th1, Th2, T reg) promote release pro-inflammatory interleukins modulate different mechanisms: membrane-receptors function; nuclear factors expression; cellular signals. Together, these alterations trigger cell death mechanisms brain neuron loss axon demyelination. hypothesis could represent remarkable approach therapies MS. Here, we also provide perspective on repositioning some already approved drugs involved other signaling pathways, strategies MS treatment.

Язык: Английский

---

Real World Experience with Cladribine Tablets for Multiple Sclerosis at Four Academic Multiple Sclerosis Centers

Multiple Sclerosis and Related Disorders, Год журнала: 2025, Номер 94, С. 106272 - 106272

Опубликована: Янв. 14, 2025

Язык: Английский

---

Attitudes of Neurologists Toward Serum Neurofilament Light-Chain Testing in the Management of Relapsing–Remitting Multiple Sclerosis with Cognitive Impairment

Journal of Personalized Medicine, Год журнала: 2025, Номер 15(2), С. 69 - 69

Опубликована: Фев. 14, 2025

Background: Cognitive impairment has an impact upon the function and quality of life patients with multiple sclerosis (MS). High-serum neurofilament light-chain (sNfL) levels predict disease progression are also associated impaired cognitive performance. This study aimed to assess attitudes neurologists toward sNfL testing as regards making therapeutic decisions in clinically radiologically stable experiencing decline. Methods: A web-based observational was conducted among caring for MS. The role assessed through a simulated case scenario describing 31-year-old woman relapsing-remitting MS four years on glatiramer acetate. Her partner reported increased distractibility difficulties organizing daily activities over past 18 months. There no history new relapses, follow-up brain MRI scan showed lesions. performance Symbol Digit Modalities Test decreased by 8 points from previous year, 46 correct answers. patient had level 21 pg/mL, other identified factors that could have altered this value. participants were tasked deciding either escalate treatment or continue current schedule reassessment 6-12 months (defined misaligned emerging evidence [DMEE]). Multivariate regression analysis determine DMEE. Results: One hundred sixteen participated study. Almost 50% (n = 57) opted not despite high levels. more common fully dedicated care (60.5% vs. 43.6%). multivariate being neurologist (odds ratio [OR] 2.35, 95% confidence interval [CI] 1.01-5.50; p 0.04) having poor perception benefits (OR 1.02, CI 1.00-1.04; 0.01) Conclusions: Neurologists' lack full dedication limited sNfL's clinical utility key suboptimal decline elevated sNfL. These findings underscore need education improve evidence-based decision-making management.

Язык: Английский

---

Choosing initial MS therapy; personal, disease, and medication factors

Neurotherapeutics, Год журнала: 2025, Номер unknown, С. e00582 - e00582

Опубликована: Апрель 1, 2025

Язык: Английский

---

Early intensive versus escalation treatment in patients with relapsing–remitting multiple sclerosis in Austria

Journal of Neurology, Год журнала: 2024, Номер 271(6), С. 3142 - 3152

Опубликована: Март 2, 2024

Abstract Objectives To compare the effectiveness of early intensive treatment (EIT) versus escalation (ESC) in a nationwide observational cohort almost 1000 people with relapsing–remitting multiple sclerosis (RRMS). Materials and methods The EIT started alemtuzumab (AZM), cladribine (CLAD), fingolimod (FTY), natalizumab (NTZ), ocrelizumab (OCR), or ozanimod (OZA); whereas, ESC was escalated from dimethylfumarate (DMF) teriflunomide (TERI) to AZM, CLAD, FTY, NTZ, OCR, OZA within Austrian MS Treatment Registry. Patients had stay on therapy for at least 3 months up 16 years. included 743 227 RRMS patients. We used multinomial propensity scores inverse probability weighting generalized linear (GLM) Cox proportional hazards models correct bias this non-randomized registry study. Results Estimated mean annualized relapse rates (ARR) were 0.09 0.4 incidence rate ratio (IRR) GLM model relapses showed decreased 78% [IRR = 0.22, 95% CI (0.16–0.30), p < 0.001]. Analyzing time first by regression, hazard (HR) 0.17 [95% (0.13–0.22), 0.001] revealed risk 83% group. Regarding sustained Expanded Disability Status Scale (EDSS) progression 12 weeks, HR 0.55 (0.40–0.76), 45% cohort. Conclusions after DMF TERI higher EDSS compared Therefore, an should be patients active highly disease course.

Язык: Английский

---

Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study

Clinical Neurology and Neurosurgery, Год журнала: 2024, Номер 240, С. 108249 - 108249

Опубликована: Март 19, 2024

Язык: Английский

---

Investigating When Patients With Multiple Sclerosis Should Switch From a Low- or Moderate-Efficacy Therapy to a High-Efficacy Treatment

Neurology, Год журнала: 2024, Номер 103(6)

Опубликована: Авг. 29, 2024

Язык: Английский

---